Vir Biotechnology insider sales: 249,060 + 2,300 shares disclosed
Rhea-AI Filing Summary
Vir Biotechnology (VIR): A reporting group affiliated with SoftBank—SVF Endurance (Cayman) Limited—reported open‑market sales of Vir common stock under a Rule 10b5‑1 trading plan entered into on September 3, 2025. On 10/09/2025, it sold 249,060 shares at a weighted average price of $6.1428. On 10/10/2025, it sold 2,300 shares at a weighted average price of $6.0752.
Following these transactions, the filing shows beneficial ownership of 15,372,309 shares after the first sale and 15,370,009 shares after the second, held indirectly, with SVF Endurance as record holder and SB Investment Advisers (UK) Limited managing SoftBank Vision Fund (AIV M1) L.P. The reporting person is listed as a Director and 10% Owner.
Positive
- None.
Negative
- None.
Insights
Planned insider sales by a 10% holder; neutral signal.
SVF Endurance (Cayman) Limited disclosed two small open‑market sales of VIR common stock executed under a pre‑set Rule 10b5‑1 plan. The trades were 249,060 shares at a weighted average of $6.1428 on 10/09/2025 and 2,300 shares at $6.0752 on 10/10/2025.
The filing lists post‑trade beneficial ownership of 15,372,309 shares after the first transaction and 15,370,009 after the second, held indirectly via SVF Endurance, with SB Investment Advisers (UK) Limited managing the fund entity. As these are plan‑driven sales by a Director and 10% Owner, they are commonly administrative.
Actual market impact depends on future trading activity disclosed in subsequent filings. The weighted‑average pricing and share counts are explicitly stated, and the plan adoption date anchors these as pre‑arranged.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,300 | $6.0752 | $14K |
| Sale | Common Stock | 249,060 | $6.1428 | $1.53M |
Footnotes (4)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.9625 to $6.35. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.09. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.